Table 3

Marginal structural models for patient survival and bleeding risks

	Benefit: reduced all-cause mortality				Harm: bleeding after treatment
	HR*	P value	95% CI^†		HR*	P value	95% CI^†
Aspirin treatment	0.60	<0.001	0.47	0.76	1.14	0.765	0.48	2.73
Age	1.06	<0.001	1.05	1.06	1.00	0.905	0.98	1.03
Male	1.19	0.053	1.00	1.43	2.40	0.005	1.31	4.40
Diabetes	1.42	<0.001	1.16	1.69	0.60	0.062	0.35	1.03
Cancer	3.70	<0.001	2.97	4.48	4.06	0.003	1.59	10.35
COPD	1.36	<0.001	1.16	1.63	1.15	0.644	0.64	2.06
Renal disease	1.19	0.086	0.97	1.44	1.46	0.299	0.72	2.97
Hypertension	1.61	<0.001	1.30	1.97	2.04	0.063	0.96	4.32
Lipid disorder	0.81	0.030	0.67	0.97	1.14	0.758	0.50	2.59
Alcohol abuse	1.81	<0.001	1.47	2.19	1.55	0.173	0.82	2.93
Overweight	0.64	0.014	0.45	0.91	0.40	0.011	0.20	0.81